Biliary HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide

被引：7
作者：
Chen, Chien-Hung [1 ,2 ]
Jeng, Wen-Juei [2 ,3 ]
Hu, Tsung-Hui [1 ,2 ]
Liu, Yen-Chun [2 ,3 ]
Wang, Jing-Houng [1 ,2 ]
Hung, Chao-Hung [1 ,2 ]
Lu, Sheng-Nan [1 ,2 ]
Chien, Rong-Nan [2 ,3 ]
机构：
[1] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, 833,123 Ta Pei Rd, Kaohsiung, Taiwan
[2] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[3] Linkuo Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Taoyuan, Taiwan
来源：
DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 06期
关键词：
Clinical relapse; Tenofovir disoproxil fumarate; Tenofovir alafenamide; Virological relapse; CHRONIC HEPATITIS-B; VIRUS INFECTION; DOUBLE-BLIND; THERAPY; ENTECAVIR; PHASE-3;
D O I：
10.1016/j.dld.2023.01.154
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Background/Aims: The incidence and relapse pattern in patients stopping tenofovir alafenamide (TAF), a prodrug of tenofovir which is more concentrated in hepatocytes, is unknown. Methods: HBeAg-negative CHB patients stopping tenofovir disoproxil fumarate (TDF) (off-TDF) or who had switched to TAF more than 3 months before discontinuation (off-TAF) were recruited. The propensity score-matching method (PSM) was used, creating a ratio of 1:3 between the off-TAF versus the off-TDF groups to adjust for associated factors. Results: After PSM, 180 off-TDF and 60 off-TAF patients were analyzed. The cumulative rates of virolog-ical and clinical relapse at 52 weeks were 75.1% and 58.5% respectively in the off-TDF group and 91.1% and 61.6% in the off-TAF group. Patients in the off-TAF group had significantly higher rates of virological relapse than those in the off-TDF group (p = 0.021), but not clinical relapse (p = 0.785). Multivariate cox regression analysis showed that off-TAF group was an independent factor for virological relapse, but not clinical relapse. Severity of clinical relapse and hepatic decompensation rate were comparable between off-TDF and off-TAF groups Conclusions: The off-TAF group had a higher virological relapse rate than the off-TDF group. The differ-ence in clinical relapse pattern and severity was not clinically important between the two groups. (c) 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：771 / 777
页数：7
相关论文
共 27 条
[1]   96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection [J].
Agarwal, Kosh ;
Brunetto, Maurizia ;
Seto, Wai Kay ;
Lim, Young-Suk ;
Fung, Scott ;
Marcellin, Patrick ;
Ahn, Sang Hoon ;
Izumi, Namiki ;
Chuang, Wan-Long ;
Bae, Ho ;
Sharma, Manoj ;
Janssen, Harry L. A. ;
Pan, Calvin Q. ;
Celen, Mustafa Kemal ;
Furusyo, Norihiro ;
Shalimar, Dr ;
Yoon, Ki Tae ;
Huy Trinh ;
Flaherty, John F. ;
Gaggar, Anuj ;
Lau, Audrey H. ;
Cathcart, Andrea L. ;
Lin, Lanjia ;
Bhardwaj, Neeru ;
Suri, Vithika ;
Subramanian, G. Mani ;
Gane, Edward J. ;
Buti, Maria ;
Chan, Henry L. Y. .
JOURNAL OF HEPATOLOGY, 2018, 68 (04) :672-681
[2]   Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies [J].
Austin, Peter C. .
PHARMACEUTICAL STATISTICS, 2011, 10 (02) :150-161
[3]   Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340 [J].
Babusis, Darius ;
Phan, Truc K. ;
Lee, William A. ;
Watkins, William J. ;
Ray, Adrian S. .
MOLECULAR PHARMACEUTICS, 2013, 10 (02) :459-466
[4]   The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy [J].
Berg, Thomas ;
Lampertico, Pietro .
JOURNAL OF HEPATOLOGY, 2021, 75 (02) :474-480
[5]  
Buti M, 2016, LANCET GASTROENTEROL, V1, P90, DOI [10.1016/S2468-1253(16)30020-6, 10.1016/S2468-1253(16)30107-8]
[6]   Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial [J].
Chan, Henry L. Y. ;
Fung, Scott ;
Seto, Wai Kay ;
Chuang, Wan-Long ;
Chen, Chi-Yi ;
Kim, Hyungjoon ;
Hui, Aric Josun ;
Janssen, Harry L. A. ;
Chowdhury, Abhijit ;
Tsang, Tak Yin Owen ;
Mehta, Rajiv ;
Gane, Edward ;
Flaherty, John F. ;
Massetto, Benedetta ;
Gaggar, Anuj ;
Kitrinos, Kathryn M. ;
Lin, Lanjia ;
Subramanian, G. Mani ;
McHutchison, John G. ;
Lim, Young-Suk ;
Acharya, Subrat K. ;
Agarwal, Kosh .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (03) :185-195
[7]   The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients [J].
Chen, C-H ;
Hsu, Y-C ;
Lu, S-N ;
Hung, C-H ;
Wang, J-H ;
Lee, C-M ;
Hu, T-H .
JOURNAL OF VIRAL HEPATITIS, 2018, 25 (05) :590-597
[8]   Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection [J].
Chen, Chien-Hung ;
Hung, Chao-Hung ;
Hu, Tsung-Hui ;
Wang, Jing-Houng ;
Lu, Sheng-Nan ;
Su, Pei-Fang ;
Lee, Chuan-Mo .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) :1984-+
[9]   A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-na⟨ve and -experienced adult Taiwanese chronic hepatitis B patients [J].
Chen, Chien-Hung ;
Hu, Tsung-Hui ;
Hung, Chao-Hung ;
Lu, Sheng-Nan ;
Wang, Jing-Houng ;
Chang, Min-Hui ;
Changchien, Chi-Sin ;
Lee, Chuan-Mo .
HEPATOLOGY INTERNATIONAL, 2013, 7 (03) :832-843
[10]   Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy [J].
Chiu, Shao-Ming ;
Kuo, Yuan-Hung ;
Wang, Jing-Houng ;
Hung, Chao-Hung ;
Hu, Tsung-Hui ;
Lu, Sheng-Nan ;
Chen, Chien-Hung .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (13) :2989-+
123